ECS Botanics Holdings (ASX:ECS) reported revenue of AU$4.9 million in the fiscal second quarter ended Dec. 31, 2024, down 33% on the year-ago period, according to a Tuesday filing with the Australian bourse.
The medicinal cannabis company attributed the decline to customers' shift from medicinal cannabis oils to other dosage forms and the delayed effect of its strategic transition to the business-to-consumer model, which it is implementing in response to changing preferences.
ECS Botanics logged cash receipts of AU$4.7 million, down 28% year on year, the filing said.
It expects to generate positive cash flow within the next six months as a result of its transition to the B2C model.
ECS Botanics' shares rose 3% in recent trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。